Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2008-07-01
2008-07-01
Marschel, Ardin H. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S236200
Reexamination Certificate
active
07393869
ABSTRACT:
Methods of using thiazolidine derivatives of formula (I) to treat cancer, inflammation, or other disorders related to the activities of protein phosphatases PTPN12 or PTPN2 in a mammal are disclosed. Pharmaceutical compositions containing such derivatives are disclosed
REFERENCES:
patent: 4464382 (1984-08-01), Tanouchi et al.
patent: 4791126 (1988-12-01), Tanouchi et al.
patent: 4831045 (1989-05-01), Tanouchi et al.
patent: 4965155 (1990-10-01), Nishiguchi et al.
patent: 5227473 (1993-07-01), Kawamura et al.
patent: 5310618 (1994-05-01), Kawamura
patent: 5691367 (1997-11-01), Panetta
patent: 5726027 (1998-03-01), Olefsky
patent: 6262044 (2001-07-01), Møller et al.
patent: 6727268 (2004-04-01), Cho et al.
patent: 0047109 (1982-03-01), None
patent: 01147472 (1989-06-01), None
patent: 01172835 (1989-07-01), None
patent: 01172836 (1989-07-01), None
patent: 01173064 (1989-07-01), None
patent: WO 99/43664 (1999-09-01), None
patent: WO 99/61467 (1999-12-01), None
patent: WO 00/36111 (2000-06-01), None
patent: WO 00/76988 (2000-12-01), None
patent: WO 01/57006 (2001-08-01), None
Gorishnyi et al. Farm.ZH. 1995 (4) 50-53.
Gura (Science, 1997, 278:1041-1042).
Jain (Sci. Am., 1994, 271:58-65).
Curti (Crit. Rev. in Oncology/Hematology, 1993, 14:29-39).
Ahmad, F., et al. “Alterations in skeletal muscle protein-tyrosine phosphatase activity and expression in insulin-resistant human obesity and diabetes” J Clin Invest (Jul. 1997) 100(2):449-458.
Cool, D.E., et al., “cDNA isolated from a human T-cell library encodes a member of the protein-tyrosine-phosphatase family” PNAS USA (Jul. 1989) 86(14):5257-61.
Davidson, D., et al. “PTP-PEST, a scaffold protein tyrosine phosphatase, negatively regulates lymphocyte activation by targeting a unique set of substrates” EMBO J (2001) 20(13):3414-26.
Elchebly, M. et al. “Increased insulin sensitivity and obesity resistance in mice lacking the protein tyrosine phosphatase-1B gene” Science (Mar. 1999) 283(5407): 1544-8.
Galic, S. et al. Regulation of insulin receptor signaling by the protein tyrosine phosphatase TCPTP Mol. Cell. Biol. (Mar. 2003) 23(6): 2096-2108.
Garton, A.J., et al. “Regulation of fibroblast motility by the protein tyrosine phosphatase PTP-PEST” J Biol Chem (Feb. 1999) 274(6):3811-3818.
Gorishnii, V. Ya, et al. “Synthesis and properties of rodanine carboxyamides” Farmatsevtichnii Zhurnal (Kiev) (2001) 2:64-67.
Gorishnyi, V. Ya, et al. “Synthesis and antiphlogistic activity of 5-aryledenerhodanin-3-alkynoic acid amides” Farmatsevtichnii Zhurnal (Kiev) (1995) 4:50-53.
Gum, R.J., Gaede, L.L., Koterski, S.L., et al. “Reduction of protein tyrosine phosphatase 1B increases insulin-dependent signaling in ob/ob mice” Diabetes (Jan. 2003) 52(1):21-28.
Ibarra-Sanchez, M.J., et al. “Murine embryonic fibroblasts lacking TC-PTP display delayed G1 phase through defective NF-kappaB activation” Oncogene (2001) 20(34):4728-39.
Mitra, S. K., et al. “Inhibition of anchorage-independent cell growth, adhesion, and cyclin D1 gene expression by a dominant negative mutant of a tyrosine phosphatase” Exp Cell Res (2001) 270(1):32-44.
Radha, V., et al. “Induction of p53 dependent apoptosis upon overexpression of a nuclear protein tyrosine phosphatase” FEBS Letters (1999) 453(3):308-312.
Reiser, J., et al. “Regulation of mouse podocyte process dynamic by protein tyrosine phosphatases rapid communication” Kidney Int (2000) 57(5):2035-2042.
Takekawa, M., et al. “Chromosomal localization of the protein tyrosine phosphatase G1 gene and characterization of he aberrant transcripts in human colon cancer cells” FEBS Letters (1994) 339(3):222-228.
Yang, Q. et al., “Cloning and Expression of PTP-PEST. A Novel, Human, Nontransmembrane Protein Tyrosine Phosphatase,”The Journal of Biological Chemistry 268(9): 6622-6628, Mar. 25, 1998.
You-Ten, K.E., et al. “Impaired bone marrow microenvironment and immune function in T cell protein tyrosine phosphatase-deficient mice” J Exp Med (1997) 186(5):683-693.
Daynard Timothy S.
Kalmar Gabriel Bela
Zhang Zaihui
Gembeh Shirley V
Marschel Ardin H.
QLT Inc.
Seed IP Law Group PLLC
LandOfFree
Methods of using thiazolidine derivatives to treat cancer or... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of using thiazolidine derivatives to treat cancer or..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of using thiazolidine derivatives to treat cancer or... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2743078